title: Reply to "Response to 'Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders' by Hassan et al.".
authors: National Center for Drug Screening and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Jiangsu Province 210009, PR China. Electronic address: shangjing21cn@163.com.
authors: Shang
authors: S
authors: Jing
authors: National Center for Drug Screening and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Jiangsu Province 210009, PR China. Electronic address: waseemhassan2010@yahoo.com.
authors: Waseem
authors: W
authors: Hassan
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000209:etiology; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology / Q000378:metabolism*; D052439:Lipid Metabolism Disorders / Q000188:drug therapy / Q000378:metabolism*; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D012307:Risk Factors; D015398:Signal Transduction
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; C502936:tocilizumab